29 September 2016

NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

Final agenda

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Appraisal of Cetuximab for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (review of TA172) [ID1016]
    • 4.1. Declarations of interest – Part 1 only (open session)
    • 4.2. Introduction by Andrew Stevens – Part 1 only (open session)
    • 4.3. Presentation by Andrew Stevens – Part 1 AND part 2 (open and closed session)
    • 4.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  5. Appraisal of Dasatinib for treating imatinib-resistant chronic myeloid leukaemia and for people for whom treatment with imatinib has failed because of intolerance (part review TA241) [ID1006] AND Dasatinib for the first-line treatment of chronic myeloid leukaemia (part review of TA251) [ID1014]
    • 5.1. Declarations of interest – Part 1 only (open session)
    • 5.2. Introduction by Andrew Stevens – Part 1 only (open session)
    • 5.3. Presentation by Andrew Stevens – Part 1 AND part 2 (open and closed session)
    • 5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (review of TA296) [ID1010]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by Amanda Adler – Part 1 only (open session)
    • 6.3. Presentation by Amanda Adler – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy (review of TA295) [ID1011]
    • 7.1. Declarations of interest – Part 2 only (closed session)
    • 7.2. Introduction by Amanda Adler – Part 2 only (closed session)
    • 7.3. Presentation by Amanda Adler – Part 2 only (closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place at 10:00 on Tuesday 29 November 2016, at NICE, 11 Spring Gardens, London, SW1A 2BU.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Monday 15 September 2016Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Jon Littler.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 01 to 15 September 2016
Registration is closed.